Company
biotechnology company developing disease-modifying treatments for neurodegenerative disorders
Melbourne, VIC
Every investor coverage indicates participated in a round Alterity Therapeutics raised.
Companies Alterity Therapeutics acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Alterity Therapeutics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Alterity Therapeutics has appointed MST Financial Services to backstop its expiring listed options ahead of a pivotal Phase 3 trial of its lead drug candidate for a rare neurodegenerative disorder.
Biotech Alterity Therapeutics has signed MST Financial to backstop an option-exercise fundraising, shoring up its cash position ahead of its Phase 3 work.
Interview with Alterity Therapeutics' investor relations head on its Phase 2 results for ATH434 in Multiple System Atrophy and its push toward a pivotal Phase 3 trial.